Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1828 1
1891 1
1912 1
1913 1
1928 1
1937 1
1946 2
1947 3
1948 5
1949 4
1950 3
1951 2
1952 3
1953 2
1954 4
1955 1
1958 2
1959 4
1960 2
1961 1
1962 7
1963 4
1964 9
1965 4
1966 2
1967 6
1968 2
1969 2
1970 3
1971 7
1972 10
1973 10
1974 11
1975 9
1976 12
1977 12
1978 15
1979 12
1980 13
1981 17
1982 20
1983 13
1984 14
1985 13
1986 9
1987 14
1988 23
1989 20
1990 14
1991 30
1992 21
1993 33
1994 39
1995 30
1996 49
1997 31
1998 37
1999 37
2000 46
2001 48
2002 29
2003 51
2004 47
2005 46
2006 57
2007 44
2008 46
2009 49
2010 75
2011 87
2012 123
2013 114
2014 123
2015 167
2016 186
2017 157
2018 196
2019 183
2020 183
2021 178
2022 157
2023 160
2024 115
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,041 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. King B, et al. Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14. Lancet. 2023. PMID: 37062298 Clinical Trial.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Ezzedine K, et al. Among authors: king b. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36370907 Free article. Clinical Trial.
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.
Illes P, Müller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C, Schmalzing G, Jarvis MF, Stojilkovic SS, King BF, Di Virgilio F. Illes P, et al. Among authors: king bf. Br J Pharmacol. 2021 Feb;178(3):489-514. doi: 10.1111/bph.15299. Epub 2020 Dec 21. Br J Pharmacol. 2021. PMID: 33125712 Free PMC article. Review.
Hospitalizations and Deaths Associated with EVALI.
Werner AK, Koumans EH, Chatham-Stephens K, Salvatore PP, Armatas C, Byers P, Clark CR, Ghinai I, Holzbauer SM, Navarette KA, Danielson ML, Ellington S, Moritz ED, Petersen EE, Kiernan EA, Baldwin GT, Briss P, Jones CM, King BA, Krishnasamy V, Rose DA, Reagan-Steiner S; Lung Injury Response Mortality Working Group. Werner AK, et al. Among authors: king ba. N Engl J Med. 2020 Apr 23;382(17):1589-1598. doi: 10.1056/NEJMoa1915314. N Engl J Med. 2020. PMID: 32320569 Free PMC article.
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Kwon O, et al. Among authors: king b. Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. Am J Clin Dermatol. 2023. PMID: 36855020 Free PMC article. Clinical Trial.
Cellular adaptation to cancer therapy along a resistance continuum.
França GS, Baron M, King BR, Bossowski JP, Bjornberg A, Pour M, Rao A, Patel AS, Misirlioglu S, Barkley D, Tang KH, Dolgalev I, Liberman DA, Avital G, Kuperwaser F, Chiodin M, Levine DA, Papagiannakopoulos T, Marusyk A, Lionnet T, Yanai I. França GS, et al. Among authors: king br. Nature. 2024 Jul;631(8022):876-883. doi: 10.1038/s41586-024-07690-9. Epub 2024 Jul 10. Nature. 2024. PMID: 38987605
e-Cigarette Use Among Youth in the United States, 2019.
Cullen KA, Gentzke AS, Sawdey MD, Chang JT, Anic GM, Wang TW, Creamer MR, Jamal A, Ambrose BK, King BA. Cullen KA, et al. Among authors: king ba. JAMA. 2019 Dec 3;322(21):2095-2103. doi: 10.1001/jama.2019.18387. JAMA. 2019. PMID: 31688912 Free PMC article.
3,041 results